Table 1.
Comparison of pharmacological effects of flavonoids against TJ of MDCK II cells.
| HST | QUE | BLI a | BLE a | |
|---|---|---|---|---|
| CLD-2 | ||||
| TJ localization | − − | − − − | − − − | − − − |
| mRNA expression | − | − − − | − | − |
| OCLN | ||||
| TJ localization | − | − | +/− | +/− |
| mRNA expression | − | − − − | n.ex. | n.ex. |
| ZO-1 expression | ||||
| TJ localization | − | − | +/− | +/− |
| mRNA expression | − | − − − | n.ex. | n.ex. |
| MDCK II cell | ||||
| Proliferation | + + | − − | +/− | − |
| Slenderer cell shape | no | yes | no | yes |
| Direct ZO1(PDZ1) interaction | yes | no | yes | yes |
| Other signaling pathways | ||||
| TGFβ | partially | partially | yes | yes |
| MEK/ERK | partially | no | partially | yes |
| Antioxidant capacity from literature | ||||
| TEAC (trolox equiv./mmol) b | 2.01 ± 0.04 | 5.72 ± 0.16 | ||
| FCR (chlorogenic acid equiv./mmol b | 0.53 ± 0.03 | 1.24 ± 0.09 | ||
| DPPH (trolox equiv./mmol) b | 0.48 ± 0.04 | 2.25 ± 0.09 | ||
| FRAP (ferrous equiv./μmol) c | 21.1 ± 0.4 | 95.9 ± 5.4 | 38.9 ± 2.5 |